Skip to main content
. Author manuscript; available in PMC: 2018 Dec 15.
Published in final edited form as: ACS Chem Biol. 2017 Nov 10;12(12):3031–3038. doi: 10.1021/acschembio.7b00869

Figure 2.

Figure 2

Expression of elevated levels of O-GlcNAc by in vitro differentiated CD8+ T cells. (A) Workflow for in vitro CD8+ T cell differentiation. Total splenocytes from OT-1 mice are exposed to SIINFEKL peptide for 3 days, followed by CD8+ T cell enrichment and treatment with either IL-2 to generate effector-like T-cells or IL-15 and IL-7 to generate memory-like T cells. (B) Cell fractions from OT-1 CD8+ T cells, naïve or in vitro activated and differentiated into effector-like or memory-like T cells, analyzed for O-GlcNAc expression with RL2 antibody.